TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tomer Izraeli
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Polyrizon successfully completed a pre-submission meeting with the FDA regarding its PL-14 Allergy Blocker nasal spray, discussing development plans, manufacturing, and clinical trial strategies for a potential product targeting the growing global allergen blocker market.

Insights
JPMpL   neutral

Mentioned as a previous employer of Zastre & Co's founding team, with no direct positive or negative implications


PLRZ   positive

The company made significant regulatory progress by completing a constructive pre-submission meeting with the FDA, discussing development strategy for PL-14 and receiving early guidance towards potential market entry